We are live on ! Find out more

Datavault AI

DVLT

Market cap $69M

0.0727 USD

-0.0025

3.32%

At close Updated Nov 3, 4:00 PM EST

Pre-market

After hours

0.0752

+0.0025

3.44%

1 day

-3.32%

5 days

6.29%

1 month

-54.56%

3 months

-79.61%

6 months

-87.02%

Year to date

-92.68%

1 year

-95.98%

5 years

-100%

10 years

-100%

About: Datavault AI Inc is a pioneering technology licensing company that owns a portfolio of patented, secure platforms designed to redefine how data is managed, valued, and monetized in the modern era. The Company's cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Sciences and Data Sciences divisions. Datavault AI's Acoustic Sciences division features WiSA, ADIO, and Sumerian patented technologies and industry-first foundational spatial and multichannel wireless, high-definition sound transmission technologies with intellectual property covering audio timing, synchronization, and multi-channel interference cancellation.

Employees: 194

Technology Software - Infrastructure

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0.6%

Neutral 98.8%

Negative 0.6%

Datavault AI Stock Crashes — Financials Cannot Be Trusted: What You Need to Know

Shares of Datavault AI Inc. (NASDAQ:DVLT) fell nearly 40% after the company told investors to stop relying on financial results stretching back to the third quarter of 2025.

Datavault AI Stock Crashes — Financials Cannot Be Trusted: What You Need to Know

Datavault AI Signs Non-Binding Letter of Intent to Acquire a 19.9% Equity Stake in DataMEDS AI in Consideration of an Expanded Technology License

PHILADELPHIA--(BUSINESS WIRE)--Datavault AI Inc. (“Datavault AI” or the “Company”) (Nasdaq: DVLT), an Artificial Intelligence Platform (“AIP”) company providing data monetization, credentialing, and real-world asset (“RWA”) tokenization, today announced that it has entered into a non-binding letter of intent (“LOI”) to acquire a 19.9% equity interest in DataMEDS AI, Inc. (NASDAQ: MEDS) (“DataMEDS”) in consideration of an expansion of its existing technology license with DataMEDS. The proposed t.

Datavault AI Signs Non-Binding Letter of Intent to Acquire a 19.9% Equity Stake in DataMEDS AI in Consideration of an Expanded Technology License

DataMeds Regains Compliance With NASDAQ Listing Standards

TAMPA, FL / ACCESS Newswire / October 20, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its super intelligence (artificial intelligence) platform EinsteinRx™ and smart contracts platform PharmacyChain™, today announced that it has received a notification letter (the "Compliance Notice") from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC ("Nasdaq") dated October 19, 2026, informing DataMEDS that it has regained compliance with Nasdaq Listing Rule 5550(b)(1) (the "Equity Rule"). In order to regain compliance with the Equity Rule, DataMEDS needed to have a minimum stockholders' equity of $2.5 million.

DataMeds Regains Compliance With NASDAQ Listing Standards

DataMeds Applauds FDA's Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health's Peptides Roadmap

Corexa Health's three divisions - pharmacy, distribution, and tech & hub - positioned to serve the emerging compounded peptide market TAMPA, FL / ACCESS Newswire / October 16, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its super intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, today applauded the issuance of a new policy proposal by the U.S. Food and Drug Administration (FDA) entitled "Interim Access Policy for Compounding Using Certain Peptides." The new proposed policy comes less than three months following the recommendation from FDA's Pharmacy Compounding Advisory Committee (PCAC) to loosen restrictions on the use of six peptides.

DataMeds Applauds FDA's Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health's Peptides Roadmap

Datavault AI Highlights Data Futures Platform Patent Amid Tokenized Stock Exemption

Allowed patent application covers asset valuation, tokenization, transaction verification, and blockchain-enabled marketplaces as a new federal framework opens the door to on-chain trading of tokenized stocks PHILADELPHIA, PA / ACCESS Newswire / October 15, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced that the U.S. Patent and Trademark Office has issued a notice of allowance for its Method and System for Data Futures Platform patent application (U.S. Patent Application No. 17/441,847), and highlighted the relevance of the disclosed technology to a significant development in the regulatory landscape for tokenized securities.

Datavault AI Highlights Data Futures Platform Patent Amid Tokenized Stock Exemption

DataMEDS Si Licenses U.S. Rights To Reboot Health AI's Direct-To-Consumer GLP-1 Weight Management Platform

Platform to be integrated into Health Lives Here app as a subscription offering TAMPA, FL / ACCESS Newswire / October 14, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its super intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, today announced that it has entered into an exclusive license, revenue sharing and marketing agreement with REBOOT Health AI, Inc. ("REBOOT") for Direct-to-Consumer (DTC) rights in the United States to REBOOT's proprietary care management platform. The Companies will work together to tailor the platform for use in the Health Lives Here mobile application for patients taking GLP-1 receptor agonist medications (the "GLP Management Platform") leveraging the patents and patent applications (the "IP") under the license.

DataMEDS Si Licenses U.S. Rights To Reboot Health AI's Direct-To-Consumer GLP-1 Weight Management Platform

Datavault AI Appoints Shareholder and Investment Executive Jeffrey Tirman to the Board of Directors

PHILADELPHIA--(BUSINESS WIRE)--Datavault AI Inc. (“Datavault AI” or the “Company”) (Nasdaq: DVLT), an Artificial Intelligence Platform (“AIP”) company providing data monetization, credentialing, and real-world asset (“RWA”) tokenization, today announced the appointment of Jeffrey Tirman to its Board of Directors, effective as of October 12, 2026. Mr. Tirman was designated by NYIAX, Inc. (“NYIAX”) in connection with Datavault AI's recently completed acquisition of NYIAX, and he previously served.

Datavault AI Appoints Shareholder and Investment Executive Jeffrey Tirman to the Board of Directors

Datavault AI to Debut Tort Token Capabilities at the Mass Torts Made Perfect Conference in Las Vegas

CEO Nathaniel T. Bradley to present on tokenization capabilities Today, October 13, at 3:45 p.m.

Datavault AI to Debut Tort Token Capabilities at the Mass Torts Made Perfect Conference in Las Vegas

DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division

Leading Health IT Company has Implemented Cost Control Measures and Refocused Remaining Workforce Towards ChemoFx® Commercialization with Hospital Systems, HMOs, GPOs and Cancer Centers TAMPA, FL / ACCESS Newswire / October 13, 2026 / DataMeds AI, Inc . (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its super intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, today announced that it has implemented cost control measures, primarily through reductions in corporate management positions, to focus the workforce spend on commercializing ChemoFx® as a diagnostic lab test to help oncologists inform their chemotherapy regimen selection, initially for gynecologic cancers only.

DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division

DataMEDS SI Announces Helomics Receives Medicaid Coverage Policy For Chemofx(R) Assay In Gynecologic Cancers

Humana adds ChemoFx® to its Medicaid Pharmacogenomics Testing coverage policy TAMPA, FL / ACCESS Newswire / October 12, 2026 / DataMeds AI, Inc . (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company vertically integrating its Health IT and physical infrastructure together with its super intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, today announced that its recently acquired CLIA-certified precision oncology laboratory subsidiary Helomics Corporation has received a Medicaid coverage determination in gynecologic cancers for the ChemoFx® Assay, a commercially available chemoresponse test that measures how a patient's live tumor cells respond to chemotherapy agents, in gynecologic cancers.

DataMEDS SI Announces Helomics Receives Medicaid Coverage Policy For Chemofx(R) Assay In Gynecologic Cancers

See News Rankings

Price charts implemented using Lightweight Charts™